Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2
Targeted drug conjugates based on Affibody molecules fused to an albumin-binding domain (ABD) for half-life extension have demonstrated potent anti-tumor activity in preclinical therapeutic studies. Furthermore, optimization of their molecular design might increase the cytotoxic effect on tumors and...
Main Authors: | Tianqi Xu, Jie Zhang, Maryam Oroujeni, Maria S. Tretyakova, Vitalina Bodenko, Mikhail V. Belousov, Anna Orlova, Vladimir Tolmachev, Anzhelika Vorobyeva, Torbjörn Gräslund |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-02-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/3/522 |
Similar Items
-
Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
by: Haozhong Ding, et al.
Published: (2021-03-01) -
Preclinical Evaluation of a New Format of <sup>68</sup>Ga- and <sup>111</sup>In-Labeled Affibody Molecule Z<sub>IGF-1R:4551</sub> for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT
by: Yongsheng Liu, et al.
Published: (2022-07-01) -
Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody<sup>®</sup> Molecules <sup>177</sup>Lu-ABY-271 and <sup>177</sup>Lu-ABY-027: Impact of DOTA Position on ABD Domain
by: Yongsheng Liu, et al.
Published: (2021-06-01) -
The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
by: Wen Yin, et al.
Published: (2021-11-01) -
Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs
by: Mohamed Altai, et al.
Published: (2018-10-01)